Home > Press > Trellis Bioscience Names Brian C. Cunningham as CEO
Trellis Bioscience, Inc., a privately held biotechnology company, announced today the appointment of Brian C. Cunningham as Chief Executive Officer. Mr. Cunningham, the President and Chief Operating Officer of Rigel Inc. from 1998 to 2003, retired from the law firm Cooley Godward Kronish, LLP, where he was "Of Counsel" in the Palo Alto office from 2003 through December 2006.
Trellis Bioscience Names Brian C. Cunningham as CEO
SOUTH SAN FRANCISCO, CA | Posted on January 18th, 2007
"Brian Cunningham brings to Trellis over 25 years of experience within the biotech and pharmaceutical industries, including both senior management roles within companies and as one of the top legal advisors within the biopharmaceutical industry for many years," said Nolan Sigal, M.D., Ph.D., President of Trellis Bioscience. "His outstanding leadership abilities and experience within emerging companies will serve Trellis well as we seek to realize the value of our novel antibody discovery platform through both corporate partnering and through the development of our own portfolio of antibody therapeutics for use in infectious disease and oncology."
"Trellis CellSpot™ screening technology, which enables the rapid identification of high quality antibodies and optimally producing cell lines too rare to be easily found by other approaches, can help shorten development timelines and rescue failed projects while remaining compatible with existing diversity-generation and antibody production technologies," said Brian Cunningham. "I am excited to join this company whose technology offers such potential for both partnering and for the generation of next-generation, native human monoclonals with potentially better safety and simpler dosing."
Prior to joining Rigel, Mr. Cunningham was a partner in the Cooley law firm where he was head of the Life Sciences Group, the Health Care Group and Patent Group. From May 1982 to December 1989, he served as Vice President, Secretary and General Counsel of Genentech Inc. From 1992 to 1997 he served at various times as an Adjunct Professor of Law at the Santa Clara University School of Law. Previously, he was Associate Corporate Counsel of Monsanto Inc. in St. Louis, MO and a securities attorney at Winthrop, Stimson, Putnam & Roberts in New York City. He currently serves as a director of Synarc Inc., a privately held Radiological Clinical Research Organization in San Francisco, CA, and of MacuSight Inc, a developer of ophthalmic therapeutics. He has served as Chairman of the Board of Partners in School Innovation, a not-for-profit education reform organization, member and Chairman of the Board of the Bay Area Bioscience Center and as member of the Board of Directors of the San Mateo County Economic Development Authority. He is a member of the American Bar Association and the American Law Institute. Mr. Cunningham holds a BS in engineering science and a JD from Washington University in St Louis.
About Trellis Bioscience
Trellis Bioscience, Inc. has developed a breakthrough technology platform for discovery and selection of very rare cells that produce ideal proteins such as antibodies, selected for specificity, selectivity, affinity, secretion rate and other desired characteristics. The company’s proprietary CellSpot™ platform is at the convergence of nanotechnology, software, digital microscopy and biology and allows for a parallel evaluation of millions of cells simultaneously along more than 15 desired parameters in unprecedented detail. The technology has broad application in the discovery and production process development of therapeutic proteins. In addition to applying CellSpot™ to the discovery and manufacturing needs of partners, Trellis is developing a pipeline of native human antibodies for the treatment of infectious disease and oncology. More information about Trellis Bioscience can be found at http://www.trellisbio.com .
For more information, please click here
Trellis Bioscience, Inc.
Brian C. Cunningham, 650-616-1121
Joan Kureczka, 415-821-2413
Copyright © Business Wire
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Novel nanoparticle therapy promotes wound healing March 27th, 2015
Graphene reduces wear of alumina ceramic March 26th, 2015
Application of Graphene Oxide in Body Implants in Iran March 26th, 2015
Nanorobotic agents open the blood-brain barrier, offering hope for new brain treatments March 25th, 2015
Nanoscale worms provide new route to nano-necklace structures March 29th, 2015
Solving molybdenum disulfide's 'thin' problem: Research team increases material's light emission by twelve times March 29th, 2015
A first glimpse inside a macroscopic quantum state March 28th, 2015
DFG to Establish One Clinical Research Unit and Five Research Units: New Projects to Investigate Complications in Pregnancy, Particle Physics, Nanoparticles, Implants and Transport Planning / Approximately 13 Million Euros in Funding for an Initial Three-Year Period March 28th, 2015
Nanofilm Appoints Senior Sales/Marketing Executives: Don Tecco, Director of Optical Sales, North America and Rex Talbott, Business Director Optical Products March 23rd, 2015
KIT Increases Commitment in Asia: DAAD Funds Two New Projects: Strategic Partnerships with Chinese Universities and Communi-cation Technologies Network February 22nd, 2015
SouthWest Nanotechnologies CEO Dave Arthur Appointed to the Board of Affiliates of Rice University Professional Science Master’s Program February 13th, 2015
Nexeon Board Changes Announced January 29th, 2015